查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1371970

2030 年头孢菌素市场预测：按生成、类型、给药途径、配销通路管道、剂型、用途、最终用户和地区进行的全球分析

Cephalosporin Market Forecasts to 2030 - Global Analysis By Generation, Type, Route of Administration, Distribution Channel, Dosage Form, Application and End User and By Geography.
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，2023 年全球头孢菌素市场规模为 160 亿美元，预计预测期内年复合成长率为 5.3%，到 2030 年将达到 229.7 亿美元。

头孢菌素是一种广谱杀菌 B-内酰胺抗生素，最初是从真菌顶孢菌中开发出来的。用于治疗扁桃腺炎、支气管炎、中耳炎、淋病、肺炎等细菌性疾病，以及皮肤感染疾病、链球菌咽头炎、金黄色葡萄球菌感染疾病等。它抑制敏感细菌的细胞壁酶并抑制细胞合成。头孢菌素主要用于预防和治疗细菌引起的感染疾病。

根据2017年呼吸系统疾病全球影响报告，下呼吸道感染和肺炎是两大死因，每年约400万人死亡。 2015年，有920,136名5岁以下儿童死于肺炎，占该年龄层所有死亡人数的15%。肺炎链球菌是 5 岁以下儿童肺炎最常见的细菌原因，2015 年罹患了393,000 名儿童。

感染疾病流行率不断上升

头孢菌素类抗生素广泛用于治疗多种细菌感染疾病。感染疾病的增加是由多种要素造成的。主要要素之一是抗药性细菌的出现，例如抗甲氧西林金黄色葡萄球菌（MRSA）和超广谱β-内酰胺酶（ESBL）产生者。这些抗药性菌株很难用常规抗生素治疗，增加了对许多这些细菌仍然有效的头孢菌素抗生素的需求。此外，人口成长、都市化和旅游增加等要素也导致感染疾病的传播。随着越来越多的人住得更近、更频繁，感染疾病传播的风险也旅游增加。这创造了一个竞争的市场形势，为医疗保健专业人员提供了多种头孢菌素製剂。

高成本

头孢类抗生素的高成本是市场的主要抑制因素。由于复杂的製造流程、研发成本以及严格的品管措施，头孢菌素类抗生素常以高价出售。这些高成本可能会限制这些重要抗生素的获取，特别是在低收入地区和医疗保健预算有限的地区。此外，头孢菌素的高成本对医疗保健系统造成负担，导致医疗支出增加。因此，这个要素阻碍了市场的成长。

增加在各医疗领域的用途

将头孢菌素的用途扩展到其传统用途之外，为各个医学领域带来了重大机会。头孢菌素以其抗菌特性而闻名，在兽医、农业和非临床等多个领域的效用日益广泛。在兽医学中，头孢菌素用于治疗动物的细菌感染疾病，解决对动物健康和抗生素抗药性细菌可能传播给人类的担忧。在农业领域，人们正在研究头孢菌素在预防和治疗农作物和牲畜细菌感染方面的潜力。这些用途旨在透过控制植物和动物的细菌性疾病来提高农业生产力并确保食品安全。此外，头孢菌素也针对非临床目的进行了研究，例如微生物合成过程和实验室研究，证明了这种抗生素类别的多功能性超出了传统的治疗用途。这些不同的领域正在推动市场的扩张。

缺乏熟练的专业人员

由于缺乏熟练的专业人员，头孢菌素市场面临重大威胁。头孢菌素抗生素需要製造、品管和给药方面的专业知识。然而，缺乏具备处理这些业务所需技能和知识的专业人员。这种短缺影响了整体市场的生产力和效率，并可能导致药物开发、製造和分销的延迟。此外，我们满足头孢菌素类抗生素不断增长的需求的能力可能有限，特别是在感染疾病高发生率地区。因此，它成为市场需求的主要障碍。

COVID-19 的影响

COVID-19病毒的爆发对头孢菌素市场产生了重大负面影响。 COVID-19 带来的封锁、旅游限制和企业倒闭影响了许多国家的经济和部门。众多工厂和工厂的关闭对国际市场上商品的生产、交付和销售产生了不利影响。几家公司已经警告可能会出现交货延迟并减少未来的产品销售。从确诊病例和死亡人数来看，美国、印度、巴西、俄罗斯、法国、英国、土耳其、义大利和西班牙是受影响最严重的国家。

在预测期内，呼吸道感染疾病领域预计将是最大的。

由于全球呼吸道感染疾病患病不断上升，呼吸道感染疾病（RTI）领域估计占最大份额。头孢菌素是一种抗生素，广泛用于治疗呼吸道感染疾病，包括肺炎、支气管炎和鼻窦。它对多种细菌有效，包括肺炎链球菌和流感嗜血桿菌等常见呼吸道病原体，使其成为临床医生的首选。此外，抗药性细菌的出现进一步强调了头孢菌素在治疗这些感染疾病中的重要性。类似这样的持续配合措施预计将维持 RTI领域的成长。

第一代头孢菌素细分市场预计在预测期内年复合成长率最高

预计第一代头孢菌素细分市场在预测期内将出现良好成长。这些抗生素属于早期头孢菌素，对革兰氏阳性菌（包括葡萄球菌和链球菌）具有广谱活性。它常用于治疗常见感染疾病，如皮肤和软组织感染疾病、尿道感染和呼吸道感染疾病。此外，第一代头孢菌素抗生素因其功效、相对成本和经过验证的安全性而受到医疗保健相关人员的高度重视。它在市场上的长期存在和良好的实绩使其成为可靠的选择，特别是对于併发症的感染疾病。因此，该领域的成长需求正在增加。

占比最高的地区

在估计期间，亚太地区占据最大的市场占有率。亚太地区是全球头孢菌素市场的主要参与者。头孢菌素是一类重要的抗生素，在该地区广泛用于治疗多种细菌感染疾病，包括呼吸道感染疾病、尿道感染以及皮肤和软组织感染疾病。此外，中国、印度、日本、韩国等东南亚国家拥有完善的製药产业，并积极致力于研发，高效创新生产头孢类药物。该地区的经济成长和医疗保健支出的增加进一步推动了头孢菌素类抗生素的需求，确保了强劲且充满希望的市场前景。

复合年复合成长率最高的地区：

预计北美在预测期内将实现盈利成长。北美地区在全球头孢菌素市场中占据重要地位，是製药进步和医疗保健基础设施的主要中心。市场成长的推动要素包括细菌感染疾病患病的增加、更容易感染疾病的老年人口的增加以及对高效医疗保健解决方案的高需求。此外，美国和加拿大等国家在北美头孢菌素市场处于领先地位。这些国家已经建立了药品製造能力，并积极进行旨在技术创新和药物研发的研发。

免费客製化服务：

订阅此报告的客户可以存取以下免费自订选项之一：

  • 公司简介
    • 其他市场参与者的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和年复合成长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第1章执行摘要

第2章前言

  • 概述
  • 利害关係人
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 调查来源
    • 主要调查来源
    • 二次调查来源
    • 先决条件

第3章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 应用分析
  • 最终用户分析
  • 新兴市场
  • 新型冠状病毒感染疾病（COVID-19）的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第5章全球头孢菌素市场：按世代

  • 第一代头孢菌素
  • 第二代头孢菌素
  • 第三代头孢菌素
  • 第四代头孢菌素
  • 第五代头孢菌素

第6章全球头孢菌素市场：依类型

  • 品牌
  • 通用的

第7章全球头孢菌素市场：依给药途径

  • 静脉
  • 口服

第8章全球头孢菌素市场：依配销通路

  • 医院药房
  • 零售药房
  • 网路药房

第9章全球头孢菌素市场：按剂型

  • 胶囊
  • 药片
  • 其他剂型

第10章全球头孢菌素市场：依用途

  • 呼吸道感染疾病
  • 耳部感染疾病
  • 性行为感染传染病
  • 皮肤感染疾病
  • 尿道感染
  • 其他用途

第11章全球头孢菌素市场：依最终用户分类

  • 医院
  • 专科诊所
  • 居家护理
  • 其他最终用户

第12章全球头孢菌素市场：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲

第13章进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第14章公司简介

  • F. Hoffmann-La Roche Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Mylan NV
  • Pfizer Inc.
  • Novartis AG
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • AstraZeneca
  • Aurobindo Pharma
  • Johnson & Johnson Private Limited
  • Cipla Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Currax Pharmaceuticals LLC
  • Novo Nordisk A/S
  • Takeda Pharmaceutical Company Limited
  • Aristo Pharmaceuticals Ltd
  • Baxter International
  • Lupin Pharmaceuticals Inc.
  • Mankind Pharma
  • Macleods Pharmaceuticals Ltd
Product Code: SMRC24026

According to Stratistics MRC, the Global Cephalosporin Market is accounted for $16.00 billion in 2023 and is expected to reach $22.97 billion by 2030 growing at a CAGR of 5.3% during the forecast period. Cephalosporin is a bactericidal, broad-spectrum, B-lactam antibiotic that was originally developed from the fungus Acremonium. It is used to treat bacterial diseases such as tonsillitis, bronchitis, otitis media, gonorrhoea, and pneumonia, as well as skin infections, strep throat, staph infections, and others. It inhibits enzymes in the cell wall of the susceptible bacteria and disrupts cell synthesis. Cephalosporin is primarily designated for prophylaxis as well as the treatment of infections caused by bacteria.

According to the 2017 Global Impact of Respiratory Disease report, lower respiratory tract infection and pneumonia are two of the leading causes of death, accounting for approximately 4 million deaths each year. In addition, pneumonia killed 920,136 children under the age of five in 2015, accounting for 15% of all deaths in this age group. Streptococcus pneumonia is still the most common bacterial cause of pneumonia in children under the age of five, affecting 393,000 children in 2015.

Market Dynamics:

Driver:

Rising prevalence of infectious diseases

Cephalosporins are a class of antibiotics that are widely used to treat a variety of bacterial infections. The increase in infectious diseases can be attributed to various factors. One of the main drivers is the emergence of drug-resistant bacteria, such as methicillin-resistant Staphylococcus aureus (MRSA) and extended-spectrum beta-lactamase (ESBL)-producing bacteria. These resistant strains are more difficult to treat with traditional antibiotics, leading to a higher demand for cephalosporins, which are still effective against many of these bacteria. Additionally, factors such as population growth, urbanisation, and increased travel have contributed to the spread of infectious diseases. As more people live in close proximity to each other and travel frequently, the risk of infection transmission is heightened. This has led to a competitive market landscape, with a wide range of cephalosporin products available to healthcare providers.

Restraint:

High cost

The high cost of cephalosporin antibiotics poses a significant restraint on the market. Cephalosporins are often priced at a premium due to the complex manufacturing processes involved, research and development expenses, and the need for stringent quality control measures. These higher costs can limit access to these vital antibiotics, especially in low-income regions or areas with limited healthcare budgets. Additionally, the high cost of cephalosporins can put a strain on healthcare systems and lead to increased healthcare expenditures. Thus, this factor is hampering market growth.

Opportunity:

Increasing applications in various medical sectors

Expanding applications of cephalosporins beyond their traditional uses presents a significant opportunity in various medical sectors. Cephalosporins, known for their antimicrobial properties, are finding increased utility in diverse domains, including veterinary medicine, agriculture, and non-clinical settings. In veterinary medicine, cephalosporins are used to treat bacterial infections in animals, addressing concerns about animal health and the potential transfer of antibiotic-resistant bacteria to humans. In agriculture, cephalosporins are being explored for their potential to prevent and treat bacterial infections in crops and livestock. These applications aim to improve agricultural productivity and ensure food safety by controlling bacterial diseases in plants and animals. Additionally, cephalosporins are being researched for non-clinical purposes, such as in microbial synthesis processes and laboratory research, showcasing the versatility of this antibiotic class beyond conventional therapeutic use. These different domains are propelling market expansion.

Threat:

Lack of skilled professionals

The cephalosporin market faces a significant threat due to a lack of skilled professionals. Cephalosporin antibiotics require expertise in their production, quality control, and administration. However, there is a shortage of professionals with the necessary skills and knowledge to handle these tasks. This shortage can impact the overall productivity and efficiency of the market, leading to potential delays in drug development, manufacturing, and distribution. Additionally, it may limit the capacity to meet the growing demand for cephalosporin antibiotics, especially in regions where the prevalence of infectious diseases is high. Therefore, it is a significant barrier to market demand.

COVID-19 Impact

The COVID-19 virus outbreak has had a significant negative influence on the cephalosporin market. Lockdowns, travel restrictions, and business closures brought on by COVID-19 have had an impact on the economies and sectors of numerous nations. The closing of numerous plants and factories has had a detrimental influence on the production, delivery schedules, and sales of goods on the international market. A few businesses have already warned of potential delivery delays and declines in future product sales. The US, India, Brazil, Russia, France, the UK, Turkey, Italy, and Spain are some of the worst affected countries in terms confirmed cases and reported deaths.

The Respiratory Tract Infection segment is expected to be the largest during the forecast period

The Respiratory Tract Infection (RTI) segment is estimated to hold the largest share, owing to the increasing prevalence of respiratory infections globally. Cephalosporins, a class of antibiotics, are widely prescribed for treating RTIs, including pneumonia, bronchitis, and sinusitis. Their effectiveness against a broad spectrum of bacteria, including common respiratory pathogens like Streptococcus pneumoniae and Haemophilus influenzae, makes them a primary choice for clinicians. Additionally, the emergence of drug-resistant bacterial strains further emphasises the importance of cephalosporins in managing these infections. This ongoing effort is expected to sustain the growth of the RTI segment

The First-generation Cephalosporin segment is expected to have the highest CAGR during the forecast period

The First-generation Cephalosporin segment is anticipated to have lucrative growth during the forecast period. These antibiotics belong to the earliest generation of cephalosporins and have a broad spectrum of activity against gramme-positive bacteria, including staphylococci and streptococci. They are often used to treat common infections like skin and soft tissue infections, urinary tract infections, and respiratory tract infections. Moreover, healthcare professionals value first-generation cephalosporins for their efficacy, relatively low cost, and proven safety profile. Their longstanding presence in the market and established track record make them a trusted choice, especially for uncomplicated infections. Therefore, there is an increasing demand for segment growth.

Region with largest share:

Asia Pacific commanded the largest market share during the extrapolated period. The Asia-Pacific region is a vital player in the global cephalosporin market. Cephalosporins, being a crucial class of antibiotics, are widely used in the region for treating various bacterial infections, including respiratory tract infections, urinary tract infections, skin and soft tissue infections, and more. Furthermore, countries like China, India, Japan, South Korea, and others in Southeast Asia have a well-established pharmaceutical industry and are actively involved in research and development to innovate and produce cephalosporin drugs efficiently. The region's economic growth and increasing healthcare expenditure further drive the demand for cephalosporin antibiotics, ensuring a robust and promising market outlook.

Region with highest CAGR:

North America is expected to witness profitable growth over the projection period. The North American region holds a prominent position in the global cephalosporin market, being a key hub for pharmaceutical advancements and healthcare infrastructure. The market's growth is propelled by factors such as the increasing prevalence of bacterial infections, a growing elderly population prone to infections, and a high demand for efficient healthcare solutions. Furthermore, countries like the United States and Canada drive the cephalosporin market in North America. These nations have well-established pharmaceutical manufacturing capabilities and robust research and development efforts aimed at innovation and drug discovery.

Key players in the market

Some of the key players in the Cephalosporin Market include: F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., Mylan N.V., Pfizer Inc., Novartis AG, GlaxoSmithKline plc, Merck & Co., Inc., AstraZeneca, Aurobindo Pharma, Johnson & Johnson Private Limited, Cipla Inc., Sun Pharmaceutical Industries Ltd., Currax Pharmaceuticals LLC, Novo Nordisk A/S, Takeda Pharmaceutical Company Limited, Aristo Pharmaceuticals Ltd, Baxter International, Lupin Pharmaceuticals Inc., Mankind Pharma and Macleods Pharmaceuticals Ltd.

Key Developments:

In September 2023, Major Cipla has announced that it acquires South Africa wholly-owned subsidiary of the Mumbai-based drug major, has inked a binding term sheet with Actor Holdings (Pty) Ltd to acquire 100 per cent of the issued ordinary shares of Actor Pharma, the drug major said in a regulatory filing. This development underpins Cipla's commitment and investment in its over-the- counter (OTC) business and supports its journey to be a leading healthcare player in South Africa.

In April 2023, Cipla signs pact with Novartis Pharma AG for diabetes drug Galvus. The perpetual license agreement is to manufacture and market the drug and its combination brands from January 2026. The agreement is subject to satisfaction of certain conditions precedent. During the interim Cipla will continue to market and distribute Galvus branded products. This deal is expected to further bolster Cipla's position in India as one of the top players in the diabetes category.

Generations Covered:

  • First-generation Cephalosporin
  • Second-generation Cephalosporin
  • Third-generation Cephalosporin
  • Fourth-generation Cephalosporin
  • Fifth-generation Cephalosporin

Types Covered:

  • Branded
  • Generic

Route of Administrations Covered:

  • Intravenous
  • Oral

Distribution Channels Covered:

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Dosage Forms Covered:

  • Capsules
  • Tablets
  • Other Dosage Forms

Applications Covered:

  • Respiratory Tract Infection
  • Ear Infection
  • Sexually Transmitted Infection
  • Skin Infection
  • Urinary Tract Infection
  • Other Applications

End Users Covered:

  • Hospitals
  • Specialty Clinics
  • Homecare
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Application Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Cephalosporin Market, By Generation

  • 5.1 Introduction
  • 5.2 First-generation Cephalosporin
  • 5.3 Second-generation Cephalosporin
  • 5.4 Third-generation Cephalosporin
  • 5.5 Fourth-generation Cephalosporin
  • 5.6 Fifth-generation Cephalosporin

6 Global Cephalosporin Market, By Type

  • 6.1 Introduction
  • 6.2 Branded
  • 6.3 Generic

7 Global Cephalosporin Market, By Route of Administration

  • 7.1 Introduction
  • 7.2 Intravenous
  • 7.3 Oral

8 Global Cephalosporin Market, By Distribution Channel

  • 8.1 Introduction
  • 8.2 Hospital Pharmacy
  • 8.3 Retail Pharmacy
  • 8.4 Online Pharmacy

9 Global Cephalosporin Market, By Dosage Form

  • 9.1 Introduction
  • 9.2 Capsules
  • 9.3 Tablets
  • 9.4 Other Dosage Forms

10 Global Cephalosporin Market, By Application

  • 10.1 Introduction
  • 10.2 Respiratory Tract Infection
  • 10.3 Ear Infection
  • 10.4 Sexually Transmitted Infection
  • 10.5 Skin Infection
  • 10.6 Urinary Tract Infection
  • 10.7 Other Applications

11 Global Cephalosporin Market, By End User

  • 11.1 Introduction
  • 11.2 Hospitals
  • 11.3 Specialty Clinics
  • 11.4 Homecare
  • 11.5 Other End Users

12 Global Cephalosporin Market, By Geography

  • 12.1 Introduction
  • 12.2 North America
    • 12.2.1 US
    • 12.2.2 Canada
    • 12.2.3 Mexico
  • 12.3 Europe
    • 12.3.1 Germany
    • 12.3.2 UK
    • 12.3.3 Italy
    • 12.3.4 France
    • 12.3.5 Spain
    • 12.3.6 Rest of Europe
  • 12.4 Asia Pacific
    • 12.4.1 Japan
    • 12.4.2 China
    • 12.4.3 India
    • 12.4.4 Australia
    • 12.4.5 New Zealand
    • 12.4.6 South Korea
    • 12.4.7 Rest of Asia Pacific
  • 12.5 South America
    • 12.5.1 Argentina
    • 12.5.2 Brazil
    • 12.5.3 Chile
    • 12.5.4 Rest of South America
  • 12.6 Middle East & Africa
    • 12.6.1 Saudi Arabia
    • 12.6.2 UAE
    • 12.6.3 Qatar
    • 12.6.4 South Africa
    • 12.6.5 Rest of Middle East & Africa

13 Key Developments

  • 13.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 13.2 Acquisitions & Mergers
  • 13.3 New Product Launch
  • 13.4 Expansions
  • 13.5 Other Key Strategies

14 Company Profiling

  • 14.1 F. Hoffmann-La Roche Ltd.
  • 14.2 Teva Pharmaceutical Industries Ltd.
  • 14.3 Mylan N.V.
  • 14.4 Pfizer Inc.
  • 14.5 Novartis AG
  • 14.6 GlaxoSmithKline plc
  • 14.7 Merck & Co., Inc.
  • 14.8 AstraZeneca
  • 14.9 Aurobindo Pharma
  • 14.10 Johnson & Johnson Private Limited
  • 14.11 Cipla Inc.
  • 14.12 Sun Pharmaceutical Industries Ltd.
  • 14.13 Currax Pharmaceuticals LLC
  • 14.14 Novo Nordisk A/S
  • 14.15 Takeda Pharmaceutical Company Limited
  • 14.16 Aristo Pharmaceuticals Ltd
  • 14.17 Baxter International
  • 14.18 Lupin Pharmaceuticals Inc.
  • 14.19 Mankind Pharma
  • 14.20 Macleods Pharmaceuticals Ltd

List of Tables

  • Table 1 Global Cephalosporin Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Cephalosporin Market Outlook, By Generation (2021-2030) ($MN)
  • Table 3 Global Cephalosporin Market Outlook, By First-generation Cephalosporin (2021-2030) ($MN)
  • Table 4 Global Cephalosporin Market Outlook, By Second-generation Cephalosporin (2021-2030) ($MN)
  • Table 5 Global Cephalosporin Market Outlook, By Third-generation Cephalosporin (2021-2030) ($MN)
  • Table 6 Global Cephalosporin Market Outlook, By Fourth-generation Cephalosporin (2021-2030) ($MN)
  • Table 7 Global Cephalosporin Market Outlook, By Fifth-generation Cephalosporin (2021-2030) ($MN)
  • Table 8 Global Cephalosporin Market Outlook, By Type (2021-2030) ($MN)
  • Table 9 Global Cephalosporin Market Outlook, By Branded (2021-2030) ($MN)
  • Table 10 Global Cephalosporin Market Outlook, By Generic (2021-2030) ($MN)
  • Table 11 Global Cephalosporin Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 12 Global Cephalosporin Market Outlook, By Intravenous (2021-2030) ($MN)
  • Table 13 Global Cephalosporin Market Outlook, By Oral (2021-2030) ($MN)
  • Table 14 Global Cephalosporin Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 15 Global Cephalosporin Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
  • Table 16 Global Cephalosporin Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
  • Table 17 Global Cephalosporin Market Outlook, By Online Pharmacy (2021-2030) ($MN)
  • Table 18 Global Cephalosporin Market Outlook, By Dosage Form (2021-2030) ($MN)
  • Table 19 Global Cephalosporin Market Outlook, By Capsules (2021-2030) ($MN)
  • Table 20 Global Cephalosporin Market Outlook, By Tablets (2021-2030) ($MN)
  • Table 21 Global Cephalosporin Market Outlook, By Other Dosage Forms (2021-2030) ($MN)
  • Table 22 Global Cephalosporin Market Outlook, By Application (2021-2030) ($MN)
  • Table 23 Global Cephalosporin Market Outlook, By Respiratory Tract Infection (2021-2030) ($MN)
  • Table 24 Global Cephalosporin Market Outlook, By Ear Infection (2021-2030) ($MN)
  • Table 25 Global Cephalosporin Market Outlook, By Sexually Transmitted Infection (2021-2030) ($MN)
  • Table 26 Global Cephalosporin Market Outlook, By Skin Infection (2021-2030) ($MN)
  • Table 27 Global Cephalosporin Market Outlook, By Urinary Tract Infection (2021-2030) ($MN)
  • Table 28 Global Cephalosporin Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 29 Global Cephalosporin Market Outlook, By End User (2021-2030) ($MN)
  • Table 30 Global Cephalosporin Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 31 Global Cephalosporin Market Outlook, By Specialty Clinics (2021-2030) ($MN)
  • Table 32 Global Cephalosporin Market Outlook, By Homecare (2021-2030) ($MN)
  • Table 33 Global Cephalosporin Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.